At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 16 Mar 2007 Discontinued - Preclinical for Skin disorders in USA (unspecified route)
- 10 Jan 2002 Preclinical development for Skin disorders in USA (Unknown route)